Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences (FBRX) EBIT Margin (2016 - 2020)

Historic EBIT Margin for Forte Biosciences (FBRX) over the last 5 years, with Q1 2020 value amounting to 1150.4%.

  • Forte Biosciences' EBIT Margin rose 1886059500.0% to 1150.4% in Q1 2020 from the same period last year, while for Mar 2020 it was 7316.46%, marking a year-over-year increase of 75930100.0%. This contributed to the annual value of 170863.89% for FY2019, which is 1706096600.0% down from last year.
  • As of Q1 2020, Forte Biosciences' EBIT Margin stood at 1150.4%, which was up 1886059500.0% from 118911.11% recorded in Q4 2019.
  • Forte Biosciences' 5-year EBIT Margin high stood at 1706.2% for Q3 2016, and its period low was 212311.11% during Q4 2018.
  • Its 5-year average for EBIT Margin is 87685.79%, with a median of 97370.0% in 2017.
  • Its EBIT Margin has fluctuated over the past 5 years, first plummeted by -1902634800bps in 2019, then soared by 1886059500bps in 2020.
  • Quarter analysis of 5 years shows Forte Biosciences' EBIT Margin stood at 1527.39% in 2016, then crashed by -7097bps to 106870.0% in 2017, then plummeted by -99bps to 212311.11% in 2018, then surged by 44bps to 118911.11% in 2019, then skyrocketed by 101bps to 1150.4% in 2020.
  • Its EBIT Margin stands at 1150.4% for Q1 2020, versus 118911.11% for Q4 2019 and 190255.56% for Q3 2019.